THE FOUNDATION FOR AIDS RESEARCH

Financials

From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.

Officers, directors and key employees

As listed on the 990 for the year ended September 30, 2025, highest compensation first.

Address and contacts

Address (IRS master file)

120 WALL STREET 13TH FLOOR, NEW YORK, NY 10005-3908

In care of

% BRADLEY JENSEN

Principal officer (990 for 2024)

KYLE CLIFFORD, 120 WALL STREET 13TH FLOOR, NEW YORK, NY 100053908

Signed the 990

SHAWN DAVIDSON, CFO & COO

Phone

(212) 806-1600

Return prepared by

PKF O'CONNOR DAVIES ADVISORY LLC

Mission

SEE SCHEDULE O

Program accomplishments

• AS A LEADING NONPROFIT, AMFAR ADVANCES SCIENTIFIC DISCOVERY TO IMPROVE GLOBAL HEALTH, WITH A PRIMARY AND ENDURING COMMITMENT TO ENDING THE HIV/AIDS EPIDEMIC. SERVING AS A CATALYST FOR BREAKTHROUGH SCIENCE, AMFAR SUPPORTS INNOVATIVE RESEARCH IN AREAS WHERE VIRUSES AND THE IMMUNE SYSTEM PLAY A DEFINING ROLE, INCLUDING CANCER, NEUROLOGICAL CONDITIONS, AGING, AUTOIMMUNE DISORDERS, AND OTHER VIRAL DISEASES. FOR FURTHER DETAILS, SEE SCHEULE O.
  Expenses $12,787,908 · grants $3,706,225 · revenue $6,132
• TREAT ASIATHE ASIA-PACIFIC REGION IS HOME TO NEARLY 7 MILLION PEOPLE LIVING WITH HIV, THE WORLD'S LARGEST EPIDEMIC AFTER THAT IN EASTERN AND SOUTHERN AFRICA, WITH 23% OF ALL NEW INFECTIONS GLOBALLY. TREATMENT COVERAGE VARIES SIGNIFICANTLY ACROSS THE REGION, WHERE PEOPLE LIVING WITH AND AT RISK FOR HIV ARE ALSO CHALLENGED BY CO-INFECTIONS SUCH AS HEPATITIS, TUBERCULOSIS, AND MENTAL HEALTH ISSUES. WITH ITS NETWORK OF 21 ADULT AND 18 PEDIATRIC SITES IN 12 COUNTRIES ACROSS THE REGION, AMFAR'S TREAT ASIA PROGRAM BRINGS RESEARCHERS, HEALTH PROFESSIONALS, AND ADVOCATES TOGETHER TO IMPROVE STANDARDS OF CARE, EXPAND ACCESS TO TREATMENT AND PREVENTION, AND SUPPORT COMMUNITY-LED MONITORING OF HEALTH NEEDS ACROSS THE REGION. CHAMPIONING DATABASE-DRIVEN RESEARCHTREAT ASIA MANAGES THE ASIA-PACIFIC SECTION OF THE INTERNATIONAL EPIDEMIOLOGY DATABASES TO EVALUATE AIDS (IEDEA), A GLOBAL COLLABORATION ESTABLISHED BY THE U.S. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES. IEDEA IS CENTRAL TO THE INTERNATIONAL RESEARCH IN WHICH TREAT ASIA PARTICIPATES, RANGING FROM STUDIES ON TREATMENT OUTCOMES, CANCER SCREENING, AND CLINICAL OUTCOMES OF PULMONARY TB, TO MENTAL HEALTH CHALLENGES FACED BY ADOLESCENTS LIVING WITH HIV. THE INFORMATION GATHERED FROM TREAT ASIA'S OBSERVATIONAL RESEARCH DATABASES CONTINUES TO INFORM THE DEVELOPMENT OF MORE EFFECTIVE RESEARCH AND TREATMENT PROGRAMS AND HELP DEFINE TREATMENT STANDARDS SPECIFIC TO HIV/AIDS IN ASIA ALONG THE CONTINUUM OF CARE. THESE DATA ALSO INFORM STUDIES ON LYMPHOMA, HEPATITIS, SUBSTANCE USE, AND ALZHEIMER'S DISEASE, AMONG OTHER CONDITIONS. OTHER MAJOR DATABASE AND COHORT STUDIES ARE FOCUSING ON HIV TREATMENT FAILURE; MANAGEMENT AND OUTCOMES OF HIV AND TB; AND MENTAL HEALTH SCREENING AND LINKAGE TO CARE STRATEGIES.SUPPORTING ADOLESCENT HEALTH RESEARCHFOR ADOLESCENTS ACROSS SOUTHEAST ASIA, WHO REPRESENT ABOUT 30% OF THE GLOBAL ADOLESCENT POPULATION, THE CHALLENGE TO STAY HEALTHY IS COMPOUNDED BY HEALTH SYSTEMS THAT SOMETIMES LACK THE CAPACITY TO ADDRESS THEIR NEEDS.IN RESPONSE TO THESE GAPS, TREAT ASIA, IN COLLABORATION WITH LONGSTANDING PARTNER CHULALONGKORN UNIVERSITY'S SCHOOL OF GLOBAL HEALTH IN BANGKOK, ORGANIZED AN ADOLESCENT HEALTH AND RESEARCH MEETING, A TRAINING WORKSHOP DESIGNED TO STRENGTHEN ADOLESCENT HEALTH SERVICES AND RESEARCH CAPACITY ACROSS SOUTHEAST ASIA, IN SEPTEMBER 2025.TREAT ASIA IS A LEADER IN RESEARCH FOCUSED ON YOUNGER PEOPLE LIVING WITH HIV, SOME OF WHOM ACQUIRED HIV PERINATALLY. STUDIES FOCUSED ON ADOLESCENTS LIVING WITH AND AT RISK FOR HIV ADDRESS MENTAL HEALTH COLLABORATIVE CARE, CANNABIS USE, HUMAN PAPILLOMAVIRUS AND CANCER RISK, AND THE ASSOCIATIONS BETWEEN RISK-TAKING BEHAVIOR AND BRAIN HEALTH. THREE MULTI-YEAR STUDIES ARE DESCRIBED BELOW.THAI-PAPAYA (THAI PROGRAM TO ACTIVELY FOLLOW PERINATAL ADOLESCENTS AND YOUNG ADULTS LIVING WITH HIV): IMPLEMENTED IN FIVE SITES IN THAILAND, THIS STUDY EXAMINES LONG-TERM HIV TREATMENT OUTCOMES OF ADOLESCENTS AND YOUNG ADULTS LIVING WITH HIV, INCLUDING RETENTION IN CARE, MORTALITY, HEALTH-RELATED QUALITY OF LIFE, AND SEXUAL AND REPRODUCTIVE HEALTH, AMONG OTHER ISSUES. SUB-STUDIES ON CARDIOVASCULAR DISEASE, STIGMA AROUND HEALTHCARE TRANSITIONS, AND BEST PRACTICES FOR HELPING YOUNGER PEOPLE TRANSITION INTO ADULT CARE ARE ALSO BEING CONDUCTED.SUICIDAL BEHAVIOR AMONG THAI ADOLESCENTS LIVING WITH HIV (S-BETAH): THIS PROSPECTIVE COHORT STUDY AIMS TO DETERMINE THE PREVALENCE OF MENTAL HEALTH DISORDERS AND SUICIDAL BEHAVIOR FOLLOWING POSITIVE SCREENING AND LINKAGE TO MENTAL HEALTH SERVICES. A FOLLOW-UP PHASE IS ASSESSING THE PREVALENCE AND INCIDENCE OF SUICIDALITY AMONG THIS POPULATION COMPARED WITH THEIR HIV-NEGATIVE AGE- AND SEX-MATCHED COUNTERPARTS. ADOLESCENT AND YOUNG ADULT NETWORK OF IEDEA (AYANI): FOCUSING ON ADOLESCENTS AGED 1524 YEARS OLD, THIS GLOBAL STUDY ASSESSES CARE TRANSITIONS, CO-MORBIDITIES, MENTAL HEALTH CHALLENGES, AND FACTORS IMPACTING TREATMENT ADHERENCE, VIRAL SUPPRESSION, CARE ENGAGEMENT, AND MORTALITY. TEN MULTIREGIONAL AYANI RESEARCH CONCEPTS ARE IN DIFFERENT STAGES OF COMPLETION.HIV, HPV, AND CERVICAL CANCER: A DEADLY NEXUSREGULAR CERVICAL CANCER SCREENINGSPAP SMEARS AND TESTING FOR HUMAN PAPILLOMAVIRUS (HPV), THE PRIMARY CAUSE OF CERVICAL CANCERHELP DETECT CANCEROUS AND PRECANCEROUS CELLS EARLY, WHEN THEY ARE MOST TREATABLE. LOW UPTAKE OF CERVICAL HEALTH SCREENINGS, COMBINED WITH THE FACT THAT WOMEN LIVING WITH HIV ARE SUSCEPTIBLE TO CHRONIC, PERSISTENT HIGH-RISK HPV INFECTION (STRAINS MORE PRONE TO LEAD TO CANCER) AND ARE SIX TIMES MORE LIKELY TO DEVELOP CERVICAL CANCER THAN WOMEN WITHOUT HIV, PROMPTED TREAT ASIA NETWORK INVESTIGATOR DR. AGUS SOMIA, OF PROF. DR. NGOERAH HOSPITAL IN BALI, INDONESIA, TO STUDY THE ISSUE IN MORE DEPTH.THE STUDY COLLECTED DATA VIA INTERVIEWS AND CLINICAL EXAMS AT HIV OUTPATIENT CLINICS TO DETERMINE THE PREVALENCE AND RISK FACTORS OF HIGH-RISK HPV AND CERVICAL DYSPLASIA IN WOMEN LIVING WITH HIV. BASED ON ITS FINDINGS, THE STUDY RECOMMENDS INCREASING HPV VACCINATION AND CERVICAL CANCER SCREENING, PARTICULARLY FOR YOUNGER WOMEN, AND SCREENING ALL WOMEN LIVING WITH HIV IN INDONESIA IN ORDER TO IMPROVE HEALTH OUTCOMES.UNDERSTANDING ALZHEIMER'S AND HIV IN ASIAALZHEIMER'S DISEASEA DISORDER INVOLVING PROGRESSIVE DEGENERATION OF THE BRAIN AFFECTING COGNITION (MEMORY, THINKING, BEHAVIOR)IS THE MOST COMMON FORM OF DEMENTIA AMONG THE GENERAL POPULATION, ACCOUNTING FOR 60% TO 80% OF CASES. THE RISK OF ALZHEIMER'S INCREASES EXPONENTIALLY WITH AGE, AND THAT RISK INCREASES IN PEOPLE LIVING WITH HIV, FOR WHOM 30% TO 50% HAVE SOME FORM OF COGNITIVE IMPAIRMENT. ACCURATE DIAGNOSIS OF ALZHEIMER'S IS CRUCIAL SO THAT PHYSICIANS CAN WORK WITH PATIENTS TO MANAGE SYMPTOMS, EXPLORE TREATMENT OPTIONS, AND IMPROVE QUALITY OF LIFE.THANKS TO AN AMFAR-SUPPORTED STUDY, LED BY DR. AKARIN HIRANSUTHIKUL, OF CHULALONGKORN UNIVERSITY IN BANGKOK, THAILAND, RESEARCHERS HAVE SHOWN THAT A NEW METHOD OF DIAGNOSING ALZHEIMER'SA BLOOD-BASED BIOMARKERCOULD BE USEFUL IN PREDICTING COGNITIVE DECLINE IN PEOPLE LIVING WITH HIV. PARTICIPANTS WERE ENROLLED FROM COHORTS IN BANGKOK, THAILAND, AND KUALA LUMPUR, MALAYSIA.FOSTERING MENTAL HEALTH RESEARCHTHE OBJECTIVE OF TREAT ASIA'S CHIMERA PROGRAM (CAPACITY DEVELOPMENT FOR HIV AND MENTAL HEALTH RESEARCH IN ASIA) IS TO ADDRESS THE DUAL AND INTERLINKED BURDENS OF HIV AND MENTAL HEALTH. CO-LED BY PRINCIPAL INVESTIGATORS DR. ANNETTE SOHN AND DR. MILTON WAINBERG OF COLUMBIA UNIVERSITY, THE PROGRAM AIMS TO BUILD GROUPS OF INVESTIGATORS WITHIN THE ASIA-PACIFIC WITH THE CAPACITY TO LEAD REGIONAL HIV-MENTAL HEALTH-IMPLEMENTATION SCIENCE RESEARCH THAT INFORMS PUBLIC HEALTH POLICY AND IMPROVES CLINICAL CARE.CHIMERA BRINGS TOGETHER STELLAR TRAINING FACULTY FROM ACADEMIC CENTERS AND PUBLIC HEALTH ORGANIZATIONS WITHIN THE REGION AND ACROSS THE WORLD, AND BUILDS ON EXISTING NIH-FUNDED MENTAL HEALTH RESEARCH BEING CONDUCTED THROUGH IEDEA ASIA-PACIFIC. THE PROGRAM WAS RENEWED BY THE NIH FOR ANOTHER FIVE YEARS IN SEPTEMBER 2025. A NEW CLASS OF SIX FELLOWS INCLUDES DR. NAROM PRAK (CAMBODIA), DR. LIM QUAN HZIUNG AND PREETHI RAGHAVAN (MALAYSIA), DR. RUTH ANNE B. HECHANOVA-CRUZ (PHILIPPINES), AND DRS. NADVADEE AUNGKAWATTANAPONG AND MAYTEEWAT CHIDDAYCHA (THAILAND). THROUGHOUT THE YEAR, THE FELLOWS MADE STRIDES IN THEIR TRAINING ACTIVITIES AND ARE PREPARING TO CONDUCT PILOT RESEARCH STUDIES AS PART OF THE CURRICULUM. SHARING RESEARCH FINDINGSTREAT ASIA INVESTIGATORS PUBLISHED 28 SCIENTIFIC PAPERS IN PEER-REVIEWED MEDICAL JOURNALS IN 2025. THESE FINDINGS ARE SHARED IN PART THROUGH THE PARTICIPATION OF TREAT ASIA IN REGIONAL AND INTERNATIONAL CONFERENCES. TREAT ASIA HAD A STRONG PRESENCE AT THE 2025 INTERNATIONAL AIDS SOCIETY CONFERENCE ON HIV SCIENCE IN KIGALI, RWANDA, IN JULY 2025, WITH TREAT ASIA STAFF AND PARTNER INVESTIGATORS DELIVERING 12 POSTERS AND PRESENTATIONS ON TOPICS RANGING FROM PREP AND MEDICATION ADHERENCE TO KIDNEY DYSFUNCTION AND MENTAL HEALTH SERVICE INTEGRATION. ABSTRACTS WERE ALSO PRESENTED AT THE INTERNATIONAL WORKSHOP ON HIV, SRHR, & ADOLESCENCE (OCTOBER 2024), THE CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (MARCH 2025), AND THE ASIA-PACIFIC AIDS AND CO-INFECTIONS CONFERENCE (JUNE 2025), AMONG OTHERS.
  Expenses $6,141,063 · grants $2,649,385
• PUBLIC INFORMATIONAMFAR TRANSLATES AND DISSEMINATES INFORMATION ON IMPORTANT HIV-RELATED RESEARCH, TREATMENT, PREVENTION, AND POLICY ISSUES FOR DIVERSE AUDIENCES TO INCREASE AWARENESS AND KNOWLEDGE OF THE PANDEMIC. AMFAR PUBLISHES A WIDE RANGE OF EDUCATIONAL MATERIALS, MAINTAINS AN INFORMATIVE WEBSITE, WORKS CLOSELY WITH THE MEDIA TO RAISE THE PROFILE OF HIV/AIDS, BOTH DOMESTICALLY AND INTERNATIONALLY, AND TO HELP ENSURE THE ACCURACY OF HIV-RELATED PRESS COVERAGE, AND ENGAGES RESPECTED PUBLIC FIGURES, SCIENTISTS, AND POLICYMAKERS IN COMMUNICATING THE NEED FOR CONTINUED RESEARCH TO DEVELOP NEW METHODS OF PREVENTION AND TREATMENT, AND A CURE FOR HIV. RAISING HIV AWARENESS ACROSS PLATFORMSAMFAR FREQUENTLY SPOTLIGHTS INFORMATION ABOUT HIV AND OTHER HEALTH CHALLENGES ACROSS DIFFERENT PLATFORMS TO REACH DIVERSE AUDIENCES.AMFAR PRODUCES PERIODICALS IN BOTH PRINT AND DIGITAL FORMATS, INCLUDING ITS NEWSLETTER, INNOVATIONS, DISTRIBUTED TO ABOUT 15,500 PEOPLE, AND A MONTHLY E-MAIL NEWSLETTER, INSIGHTS, DISTRIBUTED TO APPROXIMATELY 24,500 RECIPIENTS. THE FOUNDATION'S WEBSITEWWW.AMFAR.ORGFEATURES NEWS, INTERVIEWS, AND ORIGINAL ARTICLES COVERING HIV RESEARCH, POLICY, THE GLOBAL EPIDEMIC, AND AMFAR PROGRAMS AND ACTIVITIES. THE WEBSITE ATTRACTS AN AVERAGE OF 27,433 MONTHLY VISITS. AMFAR CREATES AND DISTRIBUTES REPORTS, PRESS RELEASES, AND UPDATES ON MAJOR HIV/AIDS ISSUES AND CONDUCTS PUBLIC SERVICE ADVERTISING CAMPAIGNS THAT HAVE BEEN INSTRUMENTAL IN EDUCATING POLICYMAKERS, HEALTHCARE PROFESSIONALS, PEOPLE LIVING WITH HIV/AIDS, AND THE PUBLIC. AMFAR'S PUBLIC INFORMATION TEAM ALSO WORKS CLOSELY WITH THE PUBLIC POLICY OFFICE AND TREAT ASIA STAFF (SEE ABOVE) TO PRODUCE A WIDE RANGE OF ISSUE BRIEFS, FACTS SHEETS, INFOGRAPHICS, AND REPORTS.FOR WORLD AIDS DAY 2024, AMFAR PARTNERED WITH MAC VIVA GLAM TO HOST A RECEPTION AND PANEL DISCUSSION TITLED "HIV/AIDS: HOW WE CAN ALL RISE TO THE CHALLENGE" ON DECEMBER 4, 2024, IN NEW YORK CITY. THE MODERATED DISCUSSION COVERED HIV CURE RESEARCH, STIGMA, AND THE ROLE OF YOUNGER PEOPLE IN ADVOCACY EFFORTS. PANELISTS INCLUDED AMFAR'S NEWLY APPOINTED VICE PRESIDENT OF RESEARCH, ANDREA GRAMATICA, PHD; ROBERT PITTS, MD, MEDICAL DIRECTOR, HIV PREVENTION AND PRIDE CENTER AT NYC HEALTH + HOSPITALS/BELLEVUE; AND KIARA ST. JAMES, CO-FOUNDER AND EXECUTIVE DIRECTOR OF NEW YORK TRANSGENDER ADVOCACY GROUP.THROUGHOUT THE YEAR, AMFAR ROLLED OUT A SOCIAL MEDIA CAMPAIGN, FACTS FOR LIFE, THAT EDUCATED FOLLOWERS ABOUT A RANGE OF HIV-RELATED TOPICS: RESEARCH, TREATMENT, TRANSMISSION RISK, PREP AND OTHER PREVENTION TOOLS, AND CURE RESEARCH, AMONG OTHERS. IN JUNE 2025, AMFAR EXHIBITED AT THE 29TH ANNUAL BROOKLYN PRIDE MULTICULTURAL FESTIVAL IN BROOKLYN, NEW YORK, TO HELP RAISE AWARENESS ABOUT HIV/AIDS AND THE VITAL WORK THE ORGANIZATION DOES.
  Expenses $3,219,765
• PUBLIC POLICYAMFAR'S PUBLIC POLICY OFFICE UNDERSCORES URGENT HIV PUBLIC POLICY ISSUES BY MAKING DATA INTERPRETABLE AND ACCESSIBLE FOR ADVOCACY. THE MISSION OF THE FOUNDATION'S POLICY PROGRAM IS TO: 1. SUPPORT EVIDENCE-BASED HIV POLICIES; 2. ADVOCATE FOR INCREASED GLOBAL, DOMESTIC, AND RESEARCH HIV DOLLARS; AND 3. ENSURE THAT EFFORTS TO END HIV ADDRESS OLD AND NEW THREATS. THE POLICY OFFICE ACCOMPLISHES THESE OBJECTIVES BY PUBLISHING IN MEDICAL JOURNALS AND GARNERING MEDIA ATTENTION, AS WELL AS THE ATTENTION OF CONGRESSIONAL MEMBERS AND OFFICES. IN FY25, THE POLICY OFFICE'S SCIENTIFIC PUBLICATIONS INCLUDED IN THREE ARTICLES IN TWO HIGHLY COMPETITIVE SOUGHT-AFTER MEDICAL JOURNALS [THE LANCET AND THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (JAMA)]. ENDING THE HIV EPIDEMIC AND OTHER HEALTH CHALLENGES IN THE U.S.THROUGHOUT THE YEAR, AMFAR MET WITH MEMBERS OF CONGRESS, SENATE AND HOUSE COMMITTEES, AND OTHER GOVERNMENT REPRESENTATIVES TO PROMOTE AN EVIDENCED-BASED RESPONSE TO THE U.S. HIV EPIDEMIC AND DISCUSS POLICY INITIATIVES. IN PARTICULAR, POLICY STAFF DEVELOPED AND SHARED RAPID-RESPONSE INFORMATION WITH STAKEHOLDERS ABOUT BEST PRACTICES IN THE DOMESTIC HIV RESPONSE, HIGHLIGHTING DOCUMENTED SUCCESSES OF THE ENDING THE HIV EPIDEMIC INITIATIVE AND THE NATIONAL INSTITUTES OF HEALTH, FOR EXAMPLE.AMFAR FOCUSED MUCH OF ITS EFFORTS ON KEEPING DOMESTIC HIV FUNDING FOR RESEARCH AND SERVICES ON TRACK AND ADDRESSING THE ELIMINATION OF THE CDC'S HIV PREVENTION PROGRAMS, PRODUCING AN UNPRECEDENTED NUMBER OF ANALYSES ON THE POSITIVE IMPACT OF HEALTH RESEARCH AND PREVENTION PROGRAMS ON THE HIV EPIDEMIC. ONE AMFAR ANALYSIS SHOWING HOW CUTS TO CDC HIV PREVENTION WOULD INCREASE NEW INFECTIONS NOT ONLY RECEIVED MEDIA ATTENTION, BUT WAS USED BY MEMBERS OF CONGRESS TO JUSTIFY CONTINUING TO FUND HIV PREVENTION. THE REMAINING POLICY ANALYSES RELEASED BY THE POLICY OFFICE EMPHASIZED THE IMPORTANCE OF FUNDING HIV SCIENCE: IGNORING SCIENCE WILL WORSEN THE HIV EPIDEMIC IN THE U.S.; THE BEST INVESTMENT YOU DIDN'T KNOW YOU MADE: HOW NIH FUNDING FUELS INNOVATION AND ECONOMIC GROWTH; HIDDEN COSTS OF CAPPING NIH INDIRECT COSTS; PRESIDENT'S TRUMP HIV PLAN IS TOO VALUABLE TO LOSE; DOMESTIC FUNDING CONTRIBUTIONS TO HEALTH; AND WHEN GRANTS END, SO DO SCIENTIFIC BREAKTHROUGHS. IN MARCH 2025, POLICY STAFF ATTENDED THE CONFERENCE ON RETROVIRUSES AND INFECTIOUS DISEASES (CROI) TO DISCUSS THE ADMINISTRATION'S POLICIES AND IMPACTS ON HIV RESEARCH AT ACADEMIC INSTITUTIONS ACROSS THE COUNTRY. IN SEPTEMBER 2025, AMFAR'S POLICY OFFICE COAUTHORED A POLICY ANALYSIS PUBLISHED IN JAMA SHOWING THAT ESTIMATED HIV PREVENTION BUDGET CUTS WOULD RESULT IN 9,000 EXCESS INFECTIONS IN THE NEXT DECADE AND COST AN ADDITIONAL $4 BILLION. ADVOCACY WORK FOCUSED ON PRESENTATIONS TO AND COLLABORATIONS WITH HIV AND HEALTH-FOCUSED ORGANIZATIONS SUCH AS SOUTHERN AIDS COALITION, GEORGETOWN LAW'S O'NEILL INSTITUTE, HUMAN RIGHTS CAMPAIGN, FUNDERS CONCERNED ABOUT AIDS, AIDS UNITED, AND LAMBDA LEGAL, AMONG OTHERS. AMFAR'S POLICY OFFICE WAS ALSO ONE OF SEVERAL NATIONAL SPONSORS OF AIDSWATCH WHICH BRINGS HUNDREDS OF HIV ADVOCATES TO WASHINGTON, D.C., TO URGE MEMBERS OF CONGRESS TO CONTINUE TO FUND HIV RESEARCH AND PROGRAMS.ALONG WITH ITS FOCUS ON HIV, THE POLICY OFFICE PARTICIPATED IN DISCUSSIONS ON A RANGE OF TOPICS, FROM WOMEN'S HEALTH TO THE INCORPORATION OF TECHNOLOGY (INCLUDING AI) INTO PUBLIC HEALTH AND HEALTHCARE DELIVERY.ENSURING GLOBAL HEALTH ACCESSAMFAR MAINTAINS AN ACTIVE ROLE IN GLOBAL ADVOCACY AND POLICY INITIATIVES, AND, IN LIGHT OF A FEDERAL-LEVEL RETREAT FROM ESTABLISHED GLOBAL HEALTH PRIORITIES, POLICY STAFF PROVIDED DATA TO GOVERNMENT OFFICIALS ABOUT THE IMPORTANCE OF PEPFAR (THE U.S. PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF), WORKED WITH ADVOCATES TO ALLEVIATE THE IMPACT OF THE FUNDING CUTS, AND PARTICIPATED IN MONTHLY MEETINGS WITH THE BUSH INSTITUTE ON PEPFAR REAUTHORIZATION AND FUNDING. AMFAR WORKED WITH OTHER ADVOCACY ORGANIZATIONS TO PUSH BACK ON THE PROPOSED $400 MILLION RECISSION CUTS TO PEPFAR.THE POLICY OFFICE PRODUCED A REPORT AND A PUBLISHED ANALYSIS THAT RECEIVED WIDESPREAD MEDIA ATTENTION, AS WELL AS CONGRESSIONAL ATTENTION IN LIGHT OF HALTING THE PEPFAR PROGRAM (REPORT: IMPACT OF STOP WORK ORDERS FOR PEPFAR PROGRAMS; SCIENTIFIC PUBLICATION: EARLY IMPACTS OF THE PEPFAR STOP WORK ORDER: A RAPID ASSESSMENT). THE POLICY OFFICE SUPPORTED CIVIL SOCIETY ORGANIZATIONS TO UNDERSTAND THE IMPACT OF THE U.S. GOVERNMENT STOP-WORK ORDERS AND TERMINATION OF GRANTS. AMFAR PARTICIPATED IN A SAVE PEPFAR MEETING ORGANIZED BY HIV ACTIVISTS AND SUPPLIED DATA ON PEPFAR TO NUMEROUS RESEARCHERS TO SUPPORT THEIR MODELING AND ADVOCACY WORK. THE POLICY OFFICE SUPPORTED COMMUNITY ADVOCACY IN GLOBAL FUND COUNTRIES TO TRACK REALLOCATION AND REPRIORITIZATION PROCESSES IN THE FACE OF GLOBAL FUND FUNDING CUTS.AMFAR ALSO MET WITH UNAIDS OFFICIALS TO DISCUSS REVISING A GLOBAL AIDS STRATEGY FOR 2026 THROUGH 2030. OTHER HIGH-LEVEL MEETINGS FOCUSED ON GLOBAL GAG RULE RESEARCH AND GLOBAL PREP ACCESS.ADDITIONALLY, AMFAR PLAYS A KEY ROLE AS A TECHNICAL ASSISTANCE PROVIDER FOR IN-COUNTRY COMMUNITY-LED MONITORING EFFORTS IN SEVEN COUNTRIESSOUTH AFRICA, LESOTHO, MALAWI, UGANDA, HAITI, AND (WITH TREAT ASIA) INDIA AND INDONESIA. IN THIS ROLE, AMFAR ENGAGES WITH LOCAL ACTIVISTS AND DATA COLLECTION TEAMS TO ENSURE HIGH-QUALITY DATA ARE PRODUCED FOR HIV SERVICE QUALITY MONITORING AND ADVOCACY INITIATIVES. AMFAR COSPONSORED AN INTERNATIONAL STUDYTHE SCOPE (SUPPORT FOR COMMUNITY ORGANIZATIONS & PRIORITIES FOR EMPOWERMENT AND IMPACT) REPORTTHAT SHOWED GLOBAL FUND-SUPPORTED HIV SERVICE DELIVERY PROGRAMS PROFOUNDLY BENEFIT FROM LOCAL EXPERTISE AND LEADERSHIP. PUBLISHED IN AUGUST 2025, THE STUDY SURVEYED 317 COMMUNITY STAKEHOLDERS ACROSS 33 COUNTRIES AND CONDUCTED IN-DEPTH CONSULTATIONS FOR STUDY DESIGN AND COMMUNITY-BASED ASSESSMENTS. IN FY2025 PUBLIC POLICY OFFICE TEAM SERVED ON SEVERAL GLOBAL HIV BOARDS, INCLUDING THE PEPFAR SCIENTIFIC ADVISORY BOARD, THE NONPROFIT CONSTITUENCY OF THE GLOBAL FUND BOARD, THE BOARD FOR THE INTERNATIONAL AIDS SOCIETY, AND THE FUNDERS CONCERNED ABOUT AIDS BOARD. EMPOWERMENT THROUGH DATAAMFAR IS AT THE FOREFRONT OF DATA COLLECTION FOR ADVOCACY PURPOSES, FORTIFYING PUBLIC HEALTH RESPONSES WITH ACCURATE INFORMATION. IN ADDITION, AMFAR MAINTAINS A SUITE OF FREE INTERACTIVE DATABASES THAT ARE INVALUABLE RESOURCES FOR INDIVIDUALS AND ORGANIZATIONS WORKING TO SECURE AND MONITOR HIV-RELATED FUNDING AND TAILOR PROGRAMS TO MEET THE NEEDS OF CLIENTS. ADVOCATES FROM AROUND THE WORLD RELY ON THESE RESOURCES TO EASILY ACCESS DATA AND PREPARE ADVOCACY INITIATIVES. THE FIVE DATABASES ARE: PEPFAR MONITORING, EVALUATION, AND REPORTING (MER.AMFAR.ORG) PEPFAR COUNTRY/REGIONAL OPERATIONAL PLANS (COPSDATA.AMFAR.ORG) KEY POPULATIONS AND KEY POPULATION INVESTMENT FUND (KPIF) DATA PROJECT (KPDATA.AMFAR.ORG) ENDING THE HIV EPIDEMIC IN THE U.S. (EHE.AMFAR.ORG) OPIOID & HEATH INDICATORS DATABASE (OPIOID.AMFAR.ORG) AMPLIFYING EXPERTISEAMFAR PARTICIPATED IN NUMEROUS PRESENTATIONS AND PANELS AT MEETINGS AND CONFERENCES THROUGHOUT THE YEAR. IN DECEMBER 2024, POLICY STAFF FACILITATED AND SUPPORTED AMFAR CEO'S APPEARANCE AT A WHITE HOUSE PANEL TO DISCUSS LESSONS LEARNED FROM THE HIV MOVEMENT FOR THE POSSIBLE ESTABLISHMENTS OF A GLOBAL CANCER FUND. IN 2025, AMFAR HELPED LAUNCH THE GLOBAL CANCER FINANCING PLATFORM AND THE HIV/HPV EXPERT WORKING GROUP, BOTH OF WHICH HIGHLIGHT WOMEN'S CANCERS.AT THE INTERNATIONAL AIDS SOCIETY CONFERENCE ON HIV SCIENCE IN JULY 2025, AMFAR PUBLIC POLICY STAFF DELIVERED SIX PRESENTATIONS. AMONG THEM, GREG MILLETT, MPH, AMFAR VP AND DIRECTOR OF PUBLIC POLICY, ALONG WITH AGNES CHETTY OF THE WORLD HEALTH ORGANIZATION (WHO), CO-FACILITATED A SYMPOSIUM TITLED, "ARE INTEGRATION AND EQUITY AT ODDS?" THAT EXAMINED HOW ADDRESSING DIFFERENT, AND OFTEN-SILOED HEALTHCARE-BASED RESPONSES TO HIV MIGHT BE COMBINED IN AN ERA OF FUNDING DECREASES. IN ADDITION, DR. JENNIFER SHERWOOD PRESENTED RESEARCH ON HOW INCREASING CERVICAL CANCER SCREENING FOR WOMEN LIVING WITH HIV IMPROVES HEALTH OUTCOMES.
  Expenses $1,963,199 · grants $30,001

What it must file and when

IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in September, so each return is due on the 15th day of the 5th month after that.

IRS record

EIN

13-3163817

Tax-exempt status

501(c)(3): Charitable, religious, educational or scientific organization

Foundation status

Publicly supported organization (170(b)(1)(A)(vi))

Donations deductible (Pub 78)

Public charity, 50% deduction limit

Exempt since

1983

Accounting year ends

September

Files

Form 990 or 990-EZ

Category (NTEE)

Medical research (H81J)

Assets (IRS master file)

$57,990,840

Income (IRS master file)

$57,092,341

Filing history

990-N: the IRS publishes only the latest e-Postcard per organization; earlier years appear here as 990.tax collects the monthly files. 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS.

Questions about THE FOUNDATION FOR AIDS RESEARCH

What is the EIN of THE FOUNDATION FOR AIDS RESEARCH?

The employer identification number (EIN) of THE FOUNDATION FOR AIDS RESEARCH is 13-3163817.

Is THE FOUNDATION FOR AIDS RESEARCH tax-exempt?

Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 1983.

Are donations to THE FOUNDATION FOR AIDS RESEARCH tax-deductible?

Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).

Which annual return does THE FOUNDATION FOR AIDS RESEARCH file?

Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.

When is the next return of THE FOUNDATION FOR AIDS RESEARCH due?

The return for tax year 2025 (the year ending September 30, 2026) is due February 15, 2027. Form 8868 extends it by six months; the 990-N cannot be extended.

When did THE FOUNDATION FOR AIDS RESEARCH last file with the IRS?

The latest return in the IRS public files is the 990 for the year ended September 2025.

Who is the principal officer of THE FOUNDATION FOR AIDS RESEARCH?

The 990 for the year ended September 30, 2025 names KYLE CLIFFORD.

Who are the officers and directors of THE FOUNDATION FOR AIDS RESEARCH?

The 990 for the year ended September 30, 2025 lists 30 people; 13 received compensation from the organization, the highest $543,683 (KEVIN FROST, CHIEF EXECUTIVE OFFICER).

How much revenue does THE FOUNDATION FOR AIDS RESEARCH have?

On its 990 for the year ended September 30, 2025 it reported revenue of $34,783,944, expenses of $33,341,549 and total assets of $57,990,840 at year end.

Other nonprofits in NEW YORK

• MICHAEL J FOX FOUNDATION FOR PARKINSONS RESEARCH
  EIN 13-4141945 · last filed 990 for 2025
• PUBLIC HEALTH SOLUTIONS
  EIN 13-5669201 · last filed 990 for 2025
• PARKINSONS FOUNDATION INC
  EIN 13-1866796 · last filed 990 for 2025
• LICR FUND INC
  EIN 13-3573053 · last filed 990 for 2024
• CARDIOVASCULAR RESEARCH FOUNDATION
  EIN 52-1752653 · last filed 990 for 2024
• GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC
  EIN 13-4128413 · last filed 990 for 2024
• INTERNATIONAL BRAIN RESEARCH ORGANIZATION
  EIN 88-4372025 · last filed 990 for 2024
• CANCER RESEARCH INSTITUTE INC
  EIN 13-1837442 · last filed 990 for 2025

All nonprofits in NEW YORK · New York · Medical research